The Magazine for Sleep Professionals
Thursday, February 5, 2026
Pfizer Inc. announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age or older. The FDA decision is primarily […]
The Biden-Harris Administration is requiring COVID-19 vaccination of eligible staff at health care facilities that participate in the Medicare and Medicaid programs. The emergency regulation issued by the Centers for Medicare & Medicaid Services (CMS) today protects those fighting this virus on the front lines while also delivering assurances to […]
The American College of Chest Physicians (CHEST), American Lung Association and American Thoracic Society released the following statement in response to the increase in COVID-19 cases and hospitalizations. “Recently, there has been a dramatic rise in COVID-19 hospitalizations due to the highly contagious Delta variant. According to the Centers for […]
UVA Health is testing an antibody cocktail, given to President Trump over the weekend, to determine if it can prevent COVID-19 infection in people who share a household with someone with the illness. UVA is part of a national phase 3 clinical trial that is testing monoclonal antibodies made by the […]
AZD1222 development expanded into a Phase III clinical trial in the US to assess its safety, efficacy and immunogenicity.1 The US trial, called D8110C00001, is funded by the Biomedical Advanced Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department […]
Smiths Medical has announced a strategic public-private partnership with Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response, and the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND). […]
Gilead Sciences, Inc. has announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigational antiviral remdesivir in hospitalized patients with severe manifestations of COVID-19 disease. The study demonstrated that patients receiving a 10-day treatment course of remdesivir achieved similar improvement in […]
